191 results on '"Sawamoto, Kazuki"'
Search Results
2. A natural Nrf2 activator glucoraphanin improves hepatic steatosis in high-fat diet-induced obese male mice associated with AMPK activation
3. Adeno-Associated Virus Gene Transfer Ameliorates Progression of Skeletal Lesions in Mucopolysaccharidosis IVA Mice.
4. A maternal high-fat diet induces fetal origins of NASH-HCC in mice
5. Regional Variation in Androgen Receptor Expression and Biomechanical Properties May Contribute to Cryptorchidism Susceptibility in the LE/orl Rat
6. Liver-Targeted AAV8 Gene Therapy Ameliorates Skeletal and Cardiovascular Pathology in a Mucopolysaccharidosis IVA Murine Model
7. Neonatal combination therapy improves some of the clinical manifestations in the Mucopolysaccharidosis type I murine model
8. Bone-Specific Drug Delivery for Osteoporosis and Rare Skeletal Disorders
9. Biomarkers in patients with mucopolysaccharidosis type II and IV
10. Critical review of current MPS guidelines and management
11. Liquid Biopsy for Pancreatic Cancer by Serum Extracellular Vesicle–Encapsulated Long Noncoding RNA HEVEPA
12. Molecular genetics and metabolism, special edition: Diagnosis, diagnosis and prognosis of Mucopolysaccharidosis IVA
13. Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future
14. Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments
15. Gene therapy for Mucopolysaccharidoses
16. Mucopolysaccharidosis IVA and glycosaminoglycans
17. A natural Nrf2 activator glucoraphanin improves hepatic steatosis in high-fat diet-induced obese male mice associated with AMPK activation
18. Activity of daily living for Morquio A syndrome
19. Obstructive airway in Morquio A syndrome, the past, the present and the future
20. Hematopoietic stem cell transplantation for Morquio A syndrome
21. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I
22. Saturable Hepatic Extraction of Gemcitabine Involves Biphasic Uptake Mediated by Nucleoside Transporters Equilibrative Nucleoside Transporter 1 and 2
23. Therapies for the bone in mucopolysaccharidoses
24. Mechanisms of Lower Maintenance Dose of Tacrolimus in Obese Patients
25. Neonatal cellular and gene therapies for mucopolysaccharidoses: the earlier the better?
26. Sex Difference Leads to Differential Gene Expression Patterns and Therapeutic Efficacy in Mucopolysaccharidosis IVA Murine Model Receiving AAV8 Gene Therapy
27. Influence of Long-term Enteral Nutrition on Pharmacokinetics of Digoxin in Rats
28. Glucoraphanin has the therapeutic potential of resolving hepatic steatosis in a murine model of diet-induced obesity
29. 391-P: The Nrf2 Activator Increases TFAM and Suppresses STING in Human Renal Proximal Tubular Cells
30. CX3CL1-CX3CR1 Signaling Deficiency Exacerbates Obesity-induced Inflammation and Insulin Resistance in Male Mice
31. CCR5 Plays a Critical Role in Obesity-Induced Adipose Tissue Inflammation and Insulin Resistance by Regulating Both Macrophage Recruitment and M1/M2 Status
32. 1845-P: Maternal Overnutrition Causes DNA Alkylation in Fetal Liver, Suppresses FasL, and Upregulates HIF-1 Signaling Pathway in Neonatal Liver in Nonalcoholic Steatohepatitis (NASH)-Based Hepatocellular Carcinoma in Offspring
33. Evading the AAV Immune Response in Mucopolysaccharidoses
34. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management.
35. Evading the AAV Immune Response in Mucopolysaccharidoses
36. Mucopolysaccharidosis IVA: Diagnosis, Treatment, and Management
37. Therapeutic options for mucopolysaccharidoses: Current and emerging treatments
38. Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model
39. Development of Substrate Degradation Enzyme Therapy for Mucopolysaccharidosis IVA Murine Model.
40. Development of AAV gene therapy for Morquio syndrome type A
41. Biomarkers in patients with mucopolysaccharidosis types II and IV
42. Enzyme replacement therapy for mucopolysaccharidoses: Past, present, and future
43. Regional Variation in Androgen Receptor Expression and Biomechanical Properties May Contribute to Cryptorchidism Susceptibility in the LE/orl Rat
44. Contribution of equilibrative nucleoside transporters 1 and 2 to gemcitabine uptake in pancreatic cancer cells
45. Gene therapy for mucopolysaccharidoses
46. Substrate degradation enzyme therapy (SDET) for mucopolysaccharidosis type IVA
47. Neonatal umbilical cord blood transplantation halts skeletal disease progression in the murine model of MPS-I
48. Development of Bone Targeting Drugs
49. Development of Bone Targeting Drugs.
50. Activities of daily living for patients with Morquio syndrome type A
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.